
Regeneron’s Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis
On Nov. 18, 2026, Regeneron Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved Livsayis™ (cemdisiran) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive, the predominant form of the disease. Livsayis is a novel, complement component factor 5 (C5)-directed small interfering RNA (siRNA) therapeutic that reduces levels of circulating C5 protein, limiting terminal complement activation, a key driver of the disease. It is the first and only approved siRNA therapy in gMG and the only FDA-approved gMG treatment administered subcutaneously four times a year.
The FDA approval was based on results from the Phase 3 NIMBLE trial. Livsayis demonstrated the following least square mean change from baseline:
- 4.5-point improvement on the Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score at 24 weeks (0.4 standard error [SE]) compared to a 2.2-point improvement with placebo (0.5 SE). This corresponded to a placebo-adjusted improvement of 2.3 points (p=0.0005). MG-ADL is a clinician-administered patient-reported assessment of daily functions impacted by gMG, such as talking, chewing, swallowing, breathing, vision and mobility. The proportion of MG-ADL responders with at least 3-point improvement at week 24 was greater for Livsayis (76.6%) compared to placebo (44.1%, p<0.001).
- 4.2-point improvement in Quantitative Myasthenia Gravis (QMG) total score at 24 weeks (0.6 SE) compared to a 1.5-point improvement with placebo (0.7 SE), corresponding to a placebo-adjusted improvement of 2.8 points (p=0.0015). QMG is a clinician-administered assessment of muscle function, including vision, speaking/swallowing, breathing and limb mobility. The proportion of QMG responders with at least a 5-point improvement at week 24 was greater for Livsayis (48.4%) compared to placebo (19.0%, p<0.001).
- Rapid onset of clinically meaningful benefit in MG-ADL (2.5 points), with improvements seen as early as two weeks of starting treatment that deepened over time.
- Sustained disease control and symptom relief through 24 weeks, with MG-ADL scores maintained and no indication of waning efficacy.
The prescribing information for Livsayis includes a Boxed Warning for serious meningococcal infections in addition to warnings and precautions for other serious infections, consistent with other FDA-approved medicines that reduce C5 activity. The most common adverse reactions (≥5%) in patients treated with Livsayis and more frequently than placebo were injection site reactions, viral infections and urinary tract infections. Livsayis is available only through a restricted program called the Livsayis Risk Evaluation and Mitigation Strategy (REMS), which is also consistent with other FDA-approved medicines that reduce C5 activity. Details of the Important Safety Information are included below.
Regeneron is committed to supporting people living with rare diseases and ensuring patients who have been prescribed Livsayis access to their medication. Regeneron’s myRARE™ program offers resources to help patients and healthcare providers, including product information, insurance benefit verification, and information about potential financial support. To learn about myRARE, visit myRARE.com or call 1-833-4my-RARE (1-833-469-7273).
A regulatory submission for Livsayis for the treatment of gMG is currently under review in the European Union, with a decision anticipated in the second half of 2027. Regulatory submissions are planned in additional markets, including Japan.
Tags:
Source: Regeneron
Credit:
